Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Elevated non-clonal bone marrow plasma cell fraction (NCPF) at diagnosis is associated with improved outcomes; 6-year OS significantly higher in NCPF-enriched pts (70.3% vs. 56.5%, p=0.0096); PFS also superior (HR 0.69, p = 0.006).”
Title: Elevated non-clonal bone marrow plasma cell fraction at diagnosis is associated with improved outcomes in multiple myeloma
Authors: Saurabh Zanwar, Dragan Jevremovic, Prashant Kapoor, Horatiu Olteanu, Francis Buadi, Pedro Horna, Wilson Gonsalves, Jansen Seheult, Gregory Otteson, Suzanne Hayman, Nadine Abdallah, Moritz Binder, Joselle Cook, Angela Dispenzieri, David Dingli, Surendra Dasari, Morie A. Gertz, Taxiarchis Kourelis, Nelson Leung, Yi Lin, Eli Muchtar, Mustaqeem Siddiqui, Megan Weivoda, Rahma Warsame, Robert A. Kyle, S.Vincent Rajkumar, Shaji Kumar
You can read the Full Article in Blood Cancer Journal.

You can find more posts featuring Robert Orlowski on OncoDaily.